UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period June 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 (State ...

Vision: Become the Leader in the Treatment of Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System with the Industry's Leading Pipeline NASDAQ: CRBP @corbuspharma www.corbuspharma.com NASDAQ: CRBP @corbuspharma www.corbuspharma.com Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or ...

Vision: Become the Leader in the Treatment of Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System with the Industry's Leading Pipeline NASDAQ: CRBP @corbuspharma www.corbuspharma.com NASDAQ: CRBP @corbuspharma www.corbuspharma.com Forward-Looking Statements 2 This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Ted Jenkins - Senior Director of IR and Corporate Communications Yuval Cohen - CEO Barbara White - Chief Medical Officer Conference Call Participants Maury Raycroft - Jefferies Leland Gershell - Oppenheimer and Company George Zavoico - B. Riley FBR Operator Greetings, and welcome to the Corbus Pharmaceuticals Quarterly Update Conference Call and Webcast. At this time, all particip ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period March 31, 2019. or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ . Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-434803 ...

Vision: Become the Leader in the Treatment of Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System with the Industry's Leading Pipeline NASDAQ: CRBP @corbuspharma www.corbuspharma.com NASDAQ: CRBP @corbuspharma www.corbuspharma.com Forward-Looking Statements 2 This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q4 2018 Earnings Conference Call March 12, 2019 8:30 AM ET Company Participants Ted Jenkins - Senior Director of IR and Corporate Communications Yuval Cohen - CEO Sean Moran - CFO Barbara White - Chief Medical Officer Craig Millian - Chief Commercial Officer Conference Call Participants Liisa Bayko - JMP Securities Brian Abrahams - RBC Capital Markets George Zavoico - B. Riley FBR Operator Greetings, and welcome to the Corbus Pharmaceuticals Quarterly Upda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________ TO ________. COMMISSION FILE NUMBER: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 (Sta ...